← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2014First marketed drug
Mar 19, 2019First NDA
Mar 19, 2019Last known activity
Oct 24, 2024
Acquired by Supernus Pharmaceuticals on Apr 22, 2025
Timeline
2010s
- Jun 1, 2010
Sage Therapeutics— Founded
2020s
- Aug 4, 2023
zuranolone— Marketing Organization
- Aug 4, 2023
zuranolone— NDA Organization
- Aug 4, 2023
zuranolone— NDA Secondary Org
- Apr 22, 2025
Supernus Pharmaceuticals— Acquired By
Drugs by trial phase (8 distinct, 48 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Alzheimer Disease
- Bipolar Disorder
- Cognitive Dysfunction
- Dementia
- Depression
- Depression, Postpartum
- Depressive Disorder
- Disease
- Essential Tremor
- Huntington Disease
- Major Depressive Disorder
- Parkinson Disease
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Sleep Initiation and Maintenance Disorders
- Status Epilepticus
- Syndrome
- Tremor
Marketed drugs (2)
Recent trials (50)
- NCT03924492Lead sponsorN/A—
- NCT06580444CollaboratorPhase 2Oct 24, 2024
- NCT05645432Lead sponsorPhase 2Mar 31, 2023
- NCT05619692Lead sponsorPhase 2Feb 28, 2023
- NCT05655507Lead sponsorPhase 1Jan 31, 2023
- NCT05655520Lead sponsorPhase 3Dec 31, 2022
- NCT05223829CollaboratorPhase 1Nov 1, 2022
- NCT05318937Lead sponsorPhase 2Jul 6, 2022
- NCT05358821Lead sponsorPhase 2Jun 22, 2022
- NCT05366751Lead sponsorPhase 2Jun 13, 2022
- NCT05254405CollaboratorPhase 4Mar 1, 2022
- NCT05314153CollaboratorEarly Phase 1Feb 23, 2022
- NCT05173012Lead sponsorPhase 2Jan 24, 2022
- NCT05059600Lead sponsorPhase 4Nov 30, 2021
- NCT05107128Lead sponsorPhase 2Nov 30, 2021
Details
- Founded
- Cambridge, GB Jun 1, 2010
- First NDA
- Mar 19, 2019
- Last known activity
- Oct 24, 2024
Designations held
- Fast track
- Priority review
- Breakthrough therapy